|
|
Blood, 15 February 2006, Vol. 107, No. 4, pp. 1342-1351.
Prepublished online as a Blood First Edition Paper on October 13, 2005; DOI 10.1182/blood-2005-08-3485.
 Previous Article | Table of Contents | Next Article 
GENE THERAPY
NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors
Zusen Fan,
Ping Yu,
Yang Wang,
Yugang Wang,
May Lynne Fu,
Wenhua Liu,
Yonglian Sun, and
Yang-Xin Fu
From the National Laboratory of Biomacromolecules and Center for Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China; and the Department of Pathology, University of Chicago, Chicago, IL.
Natural killer (NK) cells are generally reported as innate effector cells for killing virally infected and transformed cells. It is unclear how NK cells evoke adaptive immunity to eradicate tumors. We now demonstrate that the TNF superfamily member, LIGHT, known as TNFSF14 and a T-cell costimulatory molecule, is a critical ligand for the activation of NK cells. Herpesvirus entry mediator (HVEM) is expressed on NK cells, and its engagement with LIGHT mediates NK-cell activation. The expression of LIGHT inside tumors leads to rapid rejection in a NK-dependent manner. Both NK and CD8+ cells are essential but not sufficient for the rejection of tumors because mice lacking either population fail to reject the tumor. Interestingly, activated NK cells do not kill tumors directly but can facilitate the priming of tumor-specific CD8+ T cells in an IFN- –dependent manner. Conversely, intratumor depletion of either NK cells or IFN- during tumor progression disrupts CD8+ cell–mediated tumor rejection, suggesting that the tumor is the essential site for the crosstalk between NK and CD8+ cells. Furthermore, IFNG-deficient NK cells fail to effectively activate CD8+ T cells, suggesting IFN- plays an important role in NK-mediated activation of cytotoxic T lymphocytes (CTLs). Our findings establish a direct role for LIGHT in NK activation/expansion and a critical helper role of activated NK cells in priming CD8+ T cells and breaking T-cell tolerance at the tumor site.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. W. Steinberg, O. Turovskaya, R. B. Shaikh, G. Kim, D. F. McCole, K. Pfeffer, K. M. Murphy, C. F. Ware, and M. Kronenberg
A crucial role for HVEM and BTLA in preventing intestinal inflammation
J. Exp. Med.,
June 9, 2008;
205(6):
1463 - 1476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Shiraishi, Y. Ishiwata, K. Nakagawa, S. Yokochi, C. Taruki, T. Akuta, K. Ohtomo, K. Matsushima, T. Tamatani, and S. Kanegasaki
Enhancement of Antitumor Radiation Efficacy and Consistent Induction of the Abscopal Effect in Mice by ECI301, an Active Variant of Macrophage Inflammatory Protein-1{alpha}
Clin. Cancer Res.,
February 15, 2008;
14(4):
1159 - 1166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Zhang, A. Barber, and C. L. Sentman
Chimeric NKG2D Modified T Cells Inhibit Systemic T-Cell Lymphoma Growth in a Manner Involving Multiple Cytokines and Cytotoxic Pathways
Cancer Res.,
November 15, 2007;
67(22):
11029 - 11036.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-K. Heo, M.-A Yoon, S.-C. Lee, S.-A Ju, J.-H. Choi, P.-G. Suh, B. S. Kwon, and B.-S. Kim
HVEM Signaling in Monocytes Is Mediated by Intracellular Calcium Mobilization
J. Immunol.,
November 1, 2007;
179(9):
6305 - 6310.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Loeffler, G. Le'Negrate, M. Krajewska, and J. C. Reed
Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth
PNAS,
July 31, 2007;
104(31):
12879 - 12883.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Hua, Q. Zhang, and Z. Fan
Heat Shock Protein 75 (TRAP1) Antagonizes Reactive Oxygen Species Generation and Protects Cells from Granzyme M-mediated Apoptosis
J. Biol. Chem.,
July 13, 2007;
282(28):
20553 - 20560.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Lukashev, D. LePage, C. Wilson, V. Bailly, E. Garber, A. Lukashin, A. Ngam-ek, W. Zeng, N. Allaire, S. Perrin, et al.
Targeting the Lymphotoxin-{beta} Receptor with Agonist Antibodies as a Potential Cancer Therapy
Cancer Res.,
October 1, 2006;
66(19):
9617 - 9624.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
